A combination of the activation marker CD86 and the immune checkpoint marker B and T lymphocyte attenuator (BTLA) indicates a putative permissive activation state of B cell subtypes in healthy blood donors independent of age and sex | BMC Immunology | Full Text

A combination of the activation marker CD86 and the immune checkpoint marker B and T lymphocyte attenuator (BTLA) indicates a putative permissive activation state of B cell subtypes in healthy blood donors independent of age and sex | BMC Immunology | Full Text

A combination of the activation marker CD86 and the immune checkpoint marker B and T lymphocyte attenuator (BTLA) indicates a putative permissive activation state of B cell subtypes in healthy blood donors independent of age and sex

The use of anti-B cell based therapies in immune-mediated diseases targeting general B cell markers or molecules important for B cell function has increased the clinical needs of monitoring B cell subpopulations.

Authors:Susanne Axelsson, Anders Magnuson, Anna Lange, Aseel Alshamari, Elisabeth Hultgren Hörnquist and Olof Hultgren

Citation:BMC Immunology 2020 21:14

Content type:Research article

Published on: 20 March 2020

• ViewFull Text
 
• ViewPDF